{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:21:30Z","timestamp":1790083290788,"version":"4.0.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>In HLA-incompatible kidney transplantation, the efficacy of desensitization in terms of anti-HLA antibody kinetics is not well characterized. We present an overview of the course of anti-HLA antibodies throughout plasma exchange (PE) desensitization in a series of crossmatch-positive patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>All consecutive candidates in the Dutch HLA-incompatible kidney transplantation program between November 2012 and January 2022 were included. The eligibility criteria were a positive crossmatch with a living kidney donor and no options for compatible transplantation. Desensitization consisted of 5\u201310 PE with low-dose IVIg.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>A total of 16 patient-donor pairs were included. Patients had median virtual panel-reactive antibody of 99.58%. Cumulative donor-specific anti-HLA antibody (cumDSA) mean fluorescence intensity (MFI) was 31\u2009399 median, and immunodominant DSA (iDSA) MFI was 18\u2009677 for class I and 21\u2009893 for class II. Median anti-HLA antibody MFI response to desensitization was worse in class II as compared with class I (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001), particularly for HLA-DQ. Class I cumDSA MFI decreased 68% after 4 PE versus 53% in class II. The decrease between the fifth and the 10th PE sessions was modest with 21% in class I versus 9% in class II. Antibody-mediated rejection occurred in 85% of patients, with the iDSA directed to the same mismatched HLA as before desensitization, except for 3 patients, of whom 2 had vigorous rebound of antibodies to repeated mismatches (RMMs). Rebound was highest (86%) in RMM-DSA with prior grafts removed (transplantectomy n\u2005=\u20057), lower (39%) in non-RMM-DSA (n\u2005=\u200530), and lowest (11%) for RMM-DSA with in situ grafts (n\u2005=\u20055; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.018 for RMM-DSA transplantectomy versus RMM-DSA graft in situ). With a median follow-up of 59 mo, 1 patient had died resulting in a death-censored graft survival of 73%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Patients with class II DSA, and particularly those directed against HLA-DQ locus, were difficult to desensitize.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001695","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T23:08:49Z","timestamp":1724972929000},"page":"e1695","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Anti-HLA Class II Antibodies Are the Most Resistant to Desensitization in Crossmatch-positive Living-donor Kidney Transplantations: A Patient Series"],"prefix":"10.1097","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-2025","authenticated-orcid":false,"given":"Annelies E.","family":"de Weerd","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.","family":"Roelen","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel G.H.","family":"Betjes","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian C.","family":"Clahsen-van Groningen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert W.","family":"Haasnoot","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia M.L.","family":"Kho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies E.J.","family":"Reinders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joke I.","family":"Roodnat","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Severs","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonca E.","family":"Karahan","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"van de Wetering","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus MC Transplant Institute, University Medical Center, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"R1-20250313","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"R2-20250313","doi-asserted-by":"crossref","first-page":"e068769","DOI":"10.1136\/bmj-2021-068769","article-title":"Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: systematic review and meta-analysis.","volume":"376","author":"Chaudhry","year":"2022","journal-title":"BMJ"},{"key":"R3-20250313","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1681\/ASN.2014090894","article-title":"Immune sensitization and mortality in wait-listed kidney transplant candidates.","volume":"27","author":"Sapir-Pichhadze","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R4-20250313","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1111\/ajt.17182","article-title":"Scandiatransplant acceptable mismatch program\u201410 years with an effective strategy for transplanting highly sensitized patients.","volume":"22","author":"Weinreich","year":"2022","journal-title":"Am J Transplant"},{"key":"R5-20250313","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/1744666X.2018.1498335","article-title":"Transplantation in highly sensitized patients: challenges and recommendations.","volume":"14","author":"Heidt","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"R6-20250313","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.humimm.2016.10.009","article-title":"Kidney transplantation of highly sensitized recipients under the new kidney allocation system: a reflection from five different transplant centers across the United States.","volume":"78","author":"Parsons","year":"2017","journal-title":"Hum Immunol"},{"key":"R7-20250313","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/ajt.15778","article-title":"Early graft losses in paired kidney exchange: experience from 10 years of the national kidney registry.","volume":"20","author":"Verbesey","year":"2020","journal-title":"Am J Transplant"},{"key":"R8-20250313","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJMoa1508380","article-title":"Survival benefit with kidney transplants from HLA-incompatible live donors.","volume":"374","author":"Orandi","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20250313","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/ajt.12786","article-title":"Quantifying the risk of incompatible kidney transplantation: a multicenter study.","volume":"14","author":"Orandi","year":"2014","journal-title":"Am J Transplant"},{"key":"R10-20250313","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.ekir.2021.07.024","article-title":"Immortal time-bias-corrected survival of highly sensitized patients and HLA-desensitized kidney transplant recipients.","volume":"6","author":"Noble","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R11-20250313","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1034\/j.1600-6143.2003.00180.x","article-title":"Overcoming a positive crossmatch in living-donor kidney transplantation.","volume":"3","author":"Gloor","year":"2003","journal-title":"Am J Transplant"},{"key":"R12-20250313","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1012376","article-title":"Desensitization in HLA-incompatible kidney recipients and survival.","volume":"365","author":"Montgomery","year":"2011","journal-title":"N Engl J Med"},{"key":"R13-20250313","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/ajt.15364","article-title":"Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial.","volume":"19","author":"Marks","year":"2019","journal-title":"Am J Transplant"},{"key":"R14-20250313","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/TP.0000000000001330","article-title":"32 doses of bortezomib for desensitization is not well tolerated and is associated with only modest reductions in anti-HLA antibody.","volume":"101","author":"Moreno Gonzales","year":"2017","journal-title":"Transplantation"},{"key":"R15-20250313","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1097\/TXD.0000000000001139","article-title":"Marginal impact of tocilizumab monotherapy on anti-HLA alloantibodies in highly sensitized kidney transplant candidates.","volume":"7","author":"Daligault","year":"2021","journal-title":"Transplant Direct"},{"key":"R16-20250313","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/ajt.16926","article-title":"Clazakizumab for desensitization in highly sensitized patients awaiting transplantation.","volume":"22","author":"Vo","year":"2022","journal-title":"Am J Transplant"},{"key":"R17-20250313","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R18-20250313","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/TP.0000000000000064","article-title":"Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.","volume":"98","author":"Vo","year":"2014","journal-title":"Transplantation"},{"key":"R19-20250313","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/jcm10061316","article-title":"Apheresis efficacy and tolerance in the setting of HLA-incompatible kidney transplantation.","volume":"10","author":"Noble","year":"2021","journal-title":"J Clin Med"},{"key":"R20-20250313","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/ajt.15007","article-title":"Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.","volume":"19","author":"Pinelli","year":"2019","journal-title":"Am J Transplant"},{"key":"R21-20250313","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/TP.0000000000004262","article-title":"Seeking standardized definitions for HLA-incompatible kidney transplants: a systematic review.","volume":"107","author":"Jatana","year":"2023","journal-title":"Transplantation"},{"key":"R22-20250313","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 kidney meeting report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"R23-20250313","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients.","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"key":"R24-20250313","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.humimm.2018.08.008","article-title":"Minimal data reporting standards for serological testing for histocompatibility.","volume":"79","author":"Valenzuela","year":"2018","journal-title":"Hum Immunol"},{"key":"R25-20250313","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1111\/ajt.15950","article-title":"Generation and reactivity analysis of human recombinant monoclonal antibodies directed against epitopes on HLA-DR.","volume":"20","author":"Kramer","year":"2020","journal-title":"Am J Transplant"},{"key":"R26-20250313","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/TP.0000000000002516","article-title":"An easy and sensitive method to profile the antibody specificities of HLA-specific memory B cells.","volume":"103","author":"Karahan","year":"2019","journal-title":"Transplantation"},{"key":"R27-20250313","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.humimm.2005.01.032","article-title":"Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.","volume":"66","author":"Zachary","year":"2005","journal-title":"Hum Immunol"},{"key":"R28-20250313","first-page":"201","article-title":"Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.","volume":"13","author":"Rostaing","year":"2015","journal-title":"Exp Clin Transplant"},{"key":"R29-20250313","doi-asserted-by":"crossref","first-page":"e0146075","DOI":"10.1371\/journal.pone.0146075","article-title":"Outcome after desensitization in HLA or ABO-incompatible kidney transplant recipients: a single center experience.","volume":"11","author":"Kauke","year":"2016","journal-title":"PLoS One"},{"key":"R30-20250313","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.15175","article-title":"Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies.","volume":"19","author":"Schinstock","year":"2019","journal-title":"Am J Transplant"},{"key":"R31-20250313","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/SLA.0000000000002924","article-title":"IdeS (imlifidase): a novel agent that cleaves human IgG and permits successful kidney transplantation across high-strength donor-specific antibody.","volume":"268","author":"Lonze","year":"2018","journal-title":"Ann Surg"},{"key":"R32-20250313","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1111\/ajt.14752","article-title":"Sensitization in Transplantation: Assessment of Risk (STAR) 2017 working group meeting report.","volume":"18","author":"Tambur","year":"2018","journal-title":"Am J Transplant"},{"key":"R33-20250313","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/ajt.13295","article-title":"Assessing antibody strength: comparison of MFI, C1q, and titer information.","volume":"15","author":"Tambur","year":"2015","journal-title":"Am J Transplant"},{"key":"R34-20250313","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1111\/ajt.15414","article-title":"Specificity, strength, and evolution of pretransplant donor-specific HLA antibodies determine outcome after kidney transplantation.","volume":"19","author":"Senev","year":"2019","journal-title":"Am J Transplant"},{"key":"R35-20250313","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.trim.2013.05.001","article-title":"Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.","volume":"28","author":"Fidler","year":"2013","journal-title":"Transpl Immunol"},{"key":"R36-20250313","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-6143.2012.04291.x","article-title":"Five-year outcomes in living donor kidney transplants with a positive crossmatch.","volume":"13","author":"Bentall","year":"2013","journal-title":"Am J Transplant"},{"key":"R37-20250313","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.trre.2015.04.003","article-title":"Anti-human leukocyte antigen DQ antibodies in renal transplantation: are we underestimating the most frequent donor specific alloantibodies?","volume":"29","author":"Carta","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"key":"R38-20250313","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/TP.0000000000000821","article-title":"Deleterious impact of donor-specific anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation.","volume":"100","author":"Bachelet","year":"2016","journal-title":"Transplantation"},{"key":"R39-20250313","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/ajt.12982","article-title":"Quantifying renal allograft loss following early antibody-mediated rejection.","volume":"15","author":"Orandi","year":"2015","journal-title":"Am J Transplant"},{"key":"R40-20250313","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1097\/TXD.0000000000000570","article-title":"Early and sustained reduction in donor-specific antibodies in desensitized living donor kidney transplant recipients: a 3-year prospective study.","volume":"2","author":"Shaffer","year":"2016","journal-title":"Transplant Direct"},{"key":"R41-20250313","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1097\/TXD.0000000000001183","article-title":"HLA antibody incompatible renal transplantation: long-term outcomes similar to deceased donor transplantation.","volume":"7","author":"Krishnan","year":"2021","journal-title":"Transplant Direct"},{"key":"R42-20250313","doi-asserted-by":"crossref","first-page":"781491","DOI":"10.3389\/fmed.2021.781491","article-title":"Living donor kidney transplantation in patients with donor-specific HLA antibodies after desensitization with immunoadsorption.","volume":"8","author":"Kalble","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R43-20250313","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1111\/ajt.16754","article-title":"Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.","volume":"21","author":"Kjellman","year":"2021","journal-title":"Am J Transplant"},{"key":"R44-20250313","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/ajt.12807","article-title":"HLA antibody detection with solid phase assays: great expectations or expectations too great?","volume":"14","author":"Gebel","year":"2014","journal-title":"Am J Transplant"},{"key":"R45-20250313","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1681\/ASN.2014080837","article-title":"Utility of HLA antibody testing in kidney transplantation.","volume":"26","author":"Konvalinka","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R46-20250313","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/ki.2014.261","article-title":"A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.","volume":"87","author":"Jackson","year":"2015","journal-title":"Kidney Int"},{"key":"R47-20250313","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/TP.0000000000002909","article-title":"Donor-specific B cell memory in alloimmunized kidney transplant recipients: first clinical application of a novel method.","volume":"104","author":"Wehmeier","year":"2020","journal-title":"Transplantation"},{"key":"R48-20250313","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(16)31595-1","article-title":"Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis.","volume":"389","author":"Manook","year":"2017","journal-title":"Lancet"},{"key":"R49-20250313","doi-asserted-by":"crossref","first-page":"e13751","DOI":"10.1111\/ctr.13751","article-title":"Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: is there still a role for desensitization?","volume":"33","author":"Schinstock","year":"2019","journal-title":"Clin Transplant"},{"key":"R50-20250313","first-page":"335","article-title":"Imlifidase desensitization in HLA-incompatible kidney transplantation: finding the sweet spot.","volume":"108","author":"de Weerd","year":"2024","journal-title":"Transplantation"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T17:02:06Z","timestamp":1741885326000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001695","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}